Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT.
Manmeet S AhluwaliaAhmad OzairJan DrappatzXiaobu YeSen PengMatthew LeeSanhita RathHarshil D DhruvYue HaoMichael E BerensTobias WalbertMatthias HoldhoffGlenn J LesserTimothy F CloughesyAndrew E SloanNaoko TakebeMarta CouceDavid M PeereboomLouis Burt NaborsPatrick Yung WenStuart A GrossmanLisa R RogersPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
These findings confirm safety and feasibility of TRC102+TMZ for rGBM patients. They also warrant further evaluation of combination therapy in biomarker-enriched trials enrolling GBM patients with baseline hyperactivated DDR pathways.